JP2008518587A - 多細胞下成分の検出及び定量法 - Google Patents
多細胞下成分の検出及び定量法 Download PDFInfo
- Publication number
- JP2008518587A JP2008518587A JP2007533625A JP2007533625A JP2008518587A JP 2008518587 A JP2008518587 A JP 2008518587A JP 2007533625 A JP2007533625 A JP 2007533625A JP 2007533625 A JP2007533625 A JP 2007533625A JP 2008518587 A JP2008518587 A JP 2008518587A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cells
- cell
- sample
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 23
- 238000011002 quantification Methods 0.000 title abstract description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 216
- 238000000034 method Methods 0.000 claims abstract description 111
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 11
- 239000000523 sample Substances 0.000 claims description 130
- 150000007523 nucleic acids Chemical group 0.000 claims description 66
- 108020004707 nucleic acids Proteins 0.000 claims description 50
- 102000039446 nucleic acids Human genes 0.000 claims description 50
- 230000002068 genetic effect Effects 0.000 claims description 44
- 230000001605 fetal effect Effects 0.000 claims description 33
- 238000012744 immunostaining Methods 0.000 claims description 29
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 230000003287 optical effect Effects 0.000 claims description 20
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 239000002853 nucleic acid probe Substances 0.000 claims description 19
- 238000003745 diagnosis Methods 0.000 claims description 18
- 230000008774 maternal effect Effects 0.000 claims description 11
- 108010044495 Fetal Hemoglobin Proteins 0.000 claims description 7
- 210000002593 Y chromosome Anatomy 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 6
- 210000001766 X chromosome Anatomy 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 239000013611 chromosomal DNA Substances 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 abstract description 30
- 238000007901 in situ hybridization Methods 0.000 abstract description 16
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 238000001215 fluorescent labelling Methods 0.000 abstract description 3
- 238000003364 immunohistochemistry Methods 0.000 abstract description 2
- 238000012545 processing Methods 0.000 description 30
- 230000005856 abnormality Effects 0.000 description 26
- 230000008569 process Effects 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 230000000875 corresponding effect Effects 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 15
- 238000009826 distribution Methods 0.000 description 11
- 210000001124 body fluid Anatomy 0.000 description 10
- 230000002759 chromosomal effect Effects 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 201000010374 Down Syndrome Diseases 0.000 description 9
- 239000010839 body fluid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 208000037280 Trisomy Diseases 0.000 description 7
- 206010044688 Trisomy 21 Diseases 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000008707 rearrangement Effects 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000005945 translocation Effects 0.000 description 6
- 239000003656 tris buffered saline Substances 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000012800 visualization Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 208000016361 genetic disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 238000007850 in situ PCR Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- UBOKASXZHPZFRZ-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-diamine Chemical compound N1C2=CC(N)=CC(N)=C2C=C1C1=CC=CC=C1 UBOKASXZHPZFRZ-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 102100032373 Coiled-coil domain-containing protein 85B Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 201000006360 Edwards syndrome Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 101000868814 Homo sapiens Coiled-coil domain-containing protein 85B Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000009928 Patau syndrome Diseases 0.000 description 1
- 206010040453 Sex chromosomal abnormalities Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010044686 Trisomy 13 Diseases 0.000 description 1
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 1
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000004732 colorectal carcinogenesis Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011437 continuous method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000004090 human X chromosome Anatomy 0.000 description 1
- 210000001182 human Y chromosome Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010053884 trisomy 18 Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61206704P | 2004-09-22 | 2004-09-22 | |
| PCT/US2005/033964 WO2006036735A2 (en) | 2004-09-22 | 2005-09-22 | Method for detecting and quantitating multiple subcellular components |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008518587A true JP2008518587A (ja) | 2008-06-05 |
Family
ID=36119422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007533625A Pending JP2008518587A (ja) | 2004-09-22 | 2005-09-22 | 多細胞下成分の検出及び定量法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1791979A4 (zh) |
| JP (1) | JP2008518587A (zh) |
| CN (1) | CN101228283A (zh) |
| AU (1) | AU2005289765A1 (zh) |
| CA (1) | CA2580961A1 (zh) |
| WO (1) | WO2006036735A2 (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013516178A (ja) * | 2009-12-31 | 2013-05-13 | ヴェンタナ メディカル システムズ， インク． | 変異状態と遺伝子コピー数の同時検出 |
| JP2018174828A (ja) * | 2017-04-14 | 2018-11-15 | シスメックス株式会社 | 蛍光画像分析装置、蛍光画像の分析方法及びコンピュータプログラム |
| JP2018174827A (ja) * | 2017-04-14 | 2018-11-15 | シスメックス株式会社 | 蛍光画像分析装置、蛍光画像の画像処理方法及びコンピュータプログラム |
| US11521315B2 (en) | 2019-03-29 | 2022-12-06 | Sysmex Corporation | Fluorescence image analyzer and fluorescence image analyzing method |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2288903A4 (en) * | 2008-05-16 | 2012-03-21 | Biomedical Photometrics Inc | IMAGING SYSTEM WITH OPTIMIZATION OF THE DYNAMIC RANGE |
| KR20140120321A (ko) * | 2012-02-01 | 2014-10-13 | 벤타나 메디컬 시스템즈, 인코포레이티드 | 조직 샘플들에 있어서의 유전자들을 검출하는 시스템 |
| JP6231709B1 (ja) * | 2016-05-31 | 2017-11-15 | シスメックス株式会社 | 蛍光画像分析装置および分析方法 |
| CN107267628A (zh) * | 2017-07-13 | 2017-10-20 | 苏州贝康医疗器械有限公司 | 胚胎植入前染色体异常检测试剂盒 |
| CN108956431B (zh) * | 2018-08-09 | 2021-04-30 | 苏州叠代生物科技有限公司 | 一种单采血小板制品中残留细胞的检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136540A (en) * | 1994-10-03 | 2000-10-24 | Ikonisys Inc. | Automated fluorescence in situ hybridization detection of genetic abnormalities |
| US6169816B1 (en) * | 1997-05-14 | 2001-01-02 | Applied Imaging, Inc. | Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images |
-
2005
- 2005-09-22 AU AU2005289765A patent/AU2005289765A1/en not_active Abandoned
- 2005-09-22 WO PCT/US2005/033964 patent/WO2006036735A2/en active Search and Examination
- 2005-09-22 CA CA002580961A patent/CA2580961A1/en not_active Abandoned
- 2005-09-22 JP JP2007533625A patent/JP2008518587A/ja active Pending
- 2005-09-22 EP EP05798226A patent/EP1791979A4/en not_active Withdrawn
- 2005-09-22 CN CNA200580038427XA patent/CN101228283A/zh active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013516178A (ja) * | 2009-12-31 | 2013-05-13 | ヴェンタナ メディカル システムズ， インク． | 変異状態と遺伝子コピー数の同時検出 |
| JP2018174828A (ja) * | 2017-04-14 | 2018-11-15 | シスメックス株式会社 | 蛍光画像分析装置、蛍光画像の分析方法及びコンピュータプログラム |
| JP2018174827A (ja) * | 2017-04-14 | 2018-11-15 | シスメックス株式会社 | 蛍光画像分析装置、蛍光画像の画像処理方法及びコンピュータプログラム |
| US11085880B2 (en) | 2017-04-14 | 2021-08-10 | Sysmex Corporation | Fluorescence image analyzing apparatus, method of analyzing fluorescence image, and computer program |
| US11237107B2 (en) | 2017-04-14 | 2022-02-01 | Sysmex Corporation | Fluorescence image analyzing apparatus, image processing method of fluorescence image, and computer program |
| US11521315B2 (en) | 2019-03-29 | 2022-12-06 | Sysmex Corporation | Fluorescence image analyzer and fluorescence image analyzing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2580961A1 (en) | 2006-04-06 |
| WO2006036735A2 (en) | 2006-04-06 |
| AU2005289765A1 (en) | 2006-04-06 |
| WO2006036735A3 (en) | 2008-01-24 |
| EP1791979A4 (en) | 2009-07-29 |
| EP1791979A2 (en) | 2007-06-06 |
| CN101228283A (zh) | 2008-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7346200B1 (en) | Method and apparatus for computer controlled cell based diagnosis | |
| US20130078636A1 (en) | Method for detecting and quantitating multiple subcellular components | |
| KR100691043B1 (ko) | 컴퓨터 제어된 태아 세포 포함 희귀 세포 진단 방법 및 장치 | |
| US6221607B1 (en) | Automated fluorescence in situ hybridization detection of genetic abnormalities | |
| JP2008518587A (ja) | 多細胞下成分の検出及び定量法 | |
| US20140221227A1 (en) | Automated cancer diagnostic methods using fish | |
| US7901887B2 (en) | Automated cancer diagnostic methods using fish | |
| US20050042609A1 (en) | Method and system for detecting inter-chromosomal imbalance by fluorescent in situ hybridization (fish) on interphase nuclei | |
| US20030143524A1 (en) | Method and system for determining the amount, distribution and conformation of genetic material in a cell | |
| Kim et al. | Cellular imaging-based biological analysis for cancer diagnostics and drug target development |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080529 |
|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A072 Effective date: 20080603 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110927 |